USPTO serial 79368445
NEXA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 31, 2026
- Examiner
- BROWN, TINA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with NEXA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Megan K. Bowen
Megan K. Bowen Edell, Shapiro & Finnan, LLC401 North Washington Street, Suite 801Rockville, MD 20850United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; medical preparations for the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; pharmaceutical drugs, namely, pharmaceutical preparations for the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; corticosteroids; steroids, namely, dexamethasone; anti-inflammatory drugs; chemical reagents for medical purposes; chemical preparations for medical purposes, for the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; all the foregoing for or in relation to the inner ear or auditory system of a human; none of the foregoing for use in laboratory-testing or medical-transport applications, or packaged or sold primarily in connection with vials, test tubes, syringes, non-implantable cartridges, or non-implantable medical fluid containers for such applications | ACTIVE | — |
| 009 | Downloadable and recorded software for managing clinical data; computer software, recorded for data analysis, databases management, and managing data for use in the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; downloadable computer programs for data analysis, databases management, and managing data for use in the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; computer software applications, downloadable for data analysis, databases management, and managing data for use in the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; all the foregoing for use in the diagnosis, treatment, management or amelioration of inner ear or auditory system deficiencies; none of the foregoing in the field of digital imaging or digital image processing, analysis, measurement, display comparison or simulation of effects of surgical or product treatment outcomes | ACTIVE | — |
| 010 | Medical devices, namely, hearing aids, cochlear implants made from artificial materials and in-ear monitors for medical purposes, components of medical devices, namely, sound processors and cochlear implants made from artificial materials adapted for use with prosthetic hearing devices; prosthetic hearing devices and components of prosthetic hearing devices, namely, hearing aids, sound processors and cochlear implants made from artificial materials adapted for use with prosthetic hearing devices; accessories for use with prosthetic hearing devices, namely, wireless transmitters and receivers for use with hearing aids; medical implants, namely, an implanted hearing device in the nature of a cochlear implant made from artificial materials, for delivering pharmaceutical preparations, medical preparations, pharmaceutical drugs, corticosteroids, dexamethasone, anti-inflammatory drugs, chemical reagents, or chemical preparations to the inner ear or auditory system of a human; none of the foregoing for laboratory-testing or medical-transport uses, and none of the foregoing non-implantable fluid-delivery containers, cartridges, syringes, vials, or test tubes sold for such uses | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cochlear Limited
- Other trademarks owned by Cochlear Limited
- Other trademarks owned by Cochlear Limited
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named NEXA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 15, 2026 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 15, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 15, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 15, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 15, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 24, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 9, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 9, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 30, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 31, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 31, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 10, 2026 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Mar 10, 2026 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Mar 10, 2026 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Jan 17, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 17, 2024 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Dec 16, 2024 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Dec 16, 2024 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Dec 15, 2024 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Oct 12, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 27, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 27, 2024 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Sep 27, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 27, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 27, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 25, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 25, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jul 1, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 25, 2024 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 18, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 11, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jun 11, 2024 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 29, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 14, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 14, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 14, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 14, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 14, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 2, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 2, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 2, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 20, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 20, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 20, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 8, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 8, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 8, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 1, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 6, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 6, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 27, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 26, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 2, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 28, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |